1. PARTICULAR   1. PARTICULA														(	CIO	MS	FO	RM
SPECIAL PRICE   SPECIAL PRIC																		
International	SUSPECT ADVERSE REACTION REPORT																	
International								П		П		Т	Τ	$\top$	П	Т	Τ	Т
International														L	Ш			
PRIVACY PORTOR PRESENTED DESCRIPTION OF A PARTY PRESENTATION   The PRIVACY PRESENTED DESCRIPTION   THE			I. REA	CTION	INFOR	MATION												
PRIVACY   Years   Maile   Unit   2025   The STORESCHEET CONTROLL   Property	(first, last)			1	3. SEX		-	_		_		8-12				E TO		
previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available [Drug dose prescribing error] the dosage wasn't showing property/device was not displaying the dosage [Device image display issue] previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available [Incorrect dose administered by device as submerged the device in a container with ice and water, left it in the water, and it stopped displaying [Product storage error]  Case Description: This is a spontaneous report received from a Consumer (Continued on Additional Information Page)  II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) (Information Page)  III. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) (Information Page)  III. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) (Information Page)  III. SUSPECT DRUG(S) INFORMATION  15. DRUG(S) (Information Page)  III. SUSPECT DRUG(S) INFORMATION  16. ROUTES OF COMMITTERION (Information Page)  III. SUSPECT DRUG(S) INFORMATION  17. THERAPY DURACTORY  17. T	PRIVACY DOMINI	CAN REPUBLIC			Male	Unk	Day		WOTH				AE	VER	SE RE	ACTIO	N	
previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available [Drug dose prescribing error] the dosage wasn't showing property/device was not displaying the dosage [Device image display issue] previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available [Incorrect dose administered by device) as were administering 1.4 mg because 1.5 wasn't available [Incorrect dose administered by device) as were administering 1.4 mg because 1.5 wasn't available [Incorrect dose administered by device) as container with ice and water, left it in the water, and it stopped displaying [Product storage error]  Case Description: This is a spontaneous report received from a Consumer (Continued on Additional Information Page)  II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  15. SUSPECT DRUG(S) INFORMATION  15. SUSPECT DRUG(S) INFORMATION  15. SUSPECT DRUG(S) INFORMATION  16. SOULT/OBSE(S) INFORMATION  17. ORD REACTION, AMARIAN INFORMATION [InfoRMATION] [InfoRMATI	7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)								l _	PA	ATIEN	T DIE	)					
the dosage wasn't showing property/device was not displaying the dosage (Device image display issue) previouely it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available [Incorrect dose administered by device) a container with ice and water, left it in the water, and it stopped displaying [Product storage error]  Case Description: This is a spontaneous report received from a Consumer (Continued on Additional Information Page)  II. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) INFORMATION  15. SUSPECT DRUG(S) INFORMATION  15. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  16. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  17. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (Continued on Additional Information Page)  18. DRUG PROPRIES (Product generic ream) (	previously it was 1.5 mg				1.5 wası	n't available	e [Dr	ug d	ose								ENIT	
administred by device   submerged the device in a container with ice and water, left it in the water, and it stopped displaying [Product storage error]  Case Description: This is a spontaneous report received from a Consumer (Continued on Additional Information Page)  II. SUSPECT DRUG(S) INFORMATION  II. SUSPECT DRUG(S) INFORMATION  II. SUSPECT DRUG(S) INFORMATION  II. SUSPECT DRUG(S) INFORMATION  III. SUSPECT	l' • •								_					ENI				
Submerged the device in a container with ice and water, left it in the water, and it stopped displaying [Product Shorage error]  Case Description: This is a spontaneous report received from a Consumer (Continued on Additional Information Page)  II. SUSPECT DRUG(S) Information  #1 ) Genotropin Pan (SOMATROPIN) Solution for injection #2 ) Genotropin Pan (SOMATROPIN) (DEVICE CONSTITUENT) Solution  III. ROUTE(S) For ADMINISTRATION #1 ) Unknown #2 ) Unknown #1 ) Unknown #2 ) Unknown #2 ) Unknown #2 ) Unknown #2 ) Unknown #3 ) Unknown #4 ) Unknown #4 ) Unknown #4 ) Unknown #4 ) Unknown #5 ) Unknown #6	l' '	•	idministering 1.4 mg	because	1.5 wası	n't available	e [Ind	corre	ct do	se		l □					ENT	
II. SUSPECT DRUG(S) (INFORMATION   III. SUSPECT DRUG(S) (INFORMATION   III. SUSPECT DRUG(S) (INCluded genetic name)   III. SUBPLOTES   III. SUBPLOTE   II	submerged the device in a container with ice and water, left it in the water, and it stopped displaying [Product								ıct	DISABILITY OR								
II. SUSPECT DRUG(S) INFORMATION	Case Description: This	is a spontaneou	s report received fro	m a Con		nued on Ad-	dition	al Inf	orma <del>ti</del>	ion P	auc)		LIF	FE	TENIN	G		
14. SUBSECT DRUGS (include genetic anne)   14. Openation   15. Description   15. Description   16. Openation   16. Description   16. Description   16. DOUTE (S) or Administration   17. Description   17. Description   18. DOUTE (S) or Administration   17. Description   18. DOUTE (S) or Administration   17. DESCRIPTION   19. DESCRIPTI	<u> </u>		II 01105553	T D D					omia(I	ion P	age)		11	INEA	LEMIN	<u> </u>		
#1 ) Genotropin Pen (SOMATROPIN) Solution for injection #2 ) Genotropin Pen (SOMATROPIN) (DEVICE CONSTITUENT)) Solution (Continued on Additional Information Page)  15. DAILY DOSSIS) #1 ) 1.4 mg (prescribed 1.5 mg) #1 ) Unknown #2 ) Unknown #3 ) Unknown #3 ) Unknown #3 ) Unknown #4 ) Unknown	14. SUSPECT DRUG(S) (include	generic name)	II. SUSPEC	ו טאט	S) IN	FURMA	HO	N										
#1 ) Unknown #2 ) Unknown #2 ) Unknown #2 ) Unknown #2 ) Unknown #3 ) Unknown #4 )	#1 ) Genotropin Pen (SC #2 ) Genotropin Pen (SC	MATROPIN) Sol	•	<del>"</del>					ormati	ion P	age)	A	BATE	E AFT		OPPIN	G	
## 1) Unknown  1s. TheRAPY DATES(fromto) 1s.	#1 ) 1.4 mg (prescribed 1.5 mg) #1				I ) Unknown						Y	ES [	NO	×	NA .			
19. THERAPY DURATION #1 ) Unknown / 2025 #2 ) Unknown #2 ) Unknown #3 ) Unknown #4 ) Unknown #4 ) Unknown #4 ) Unknown  #5 ) Unknown  #6 ) Unknown  #6 ) Unknown  #7 ) Unknown  #8 ) Unk	17. INDICATION(S) FOR USE #1 ) Unknown						REAPPEAR AFTER											
#2 ) Unknown    #2   Unknown   #2   Unknown   #2   Unknown	18. THERAPY DATES(from/to) 19.											۱ ٫	7~	FS <b>[</b>	٦ <sub>NO</sub>	<b>Δ</b>	JΔ	
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)  23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown  IV. MANUFACTURER INFORMATION  249. NAME AND ADDRESS OF MANUFACTURER Pfizer S. A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  240. MFR CONTROL NO. PV202500072400  240. DATE RECEIVED BY MANUFACTURER O7-AUG-2025  STUDY UTERATURE O7-AUG-2025  DATE OF THIS REPORT  250. REPORT TYPE  250. NAME AND ADDRESS WITHHELD.					,	7							• • • • • • • • • • • • • • • • • • • •					
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER OT-AUG-2025  DATE OF THIS REPORT  25b. REMARKS  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.			III. CONCOMIT	ANT D	RUG(S	AND H	IST	OR'	Y									
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER O7-AUG-2025  DATE OF THIS REPORT  25b. NAME AND ADDRESS WITHHELD.	22. CONCOMITANT DRUG(S) AN	ID DATES OF ADMINIS	STRATION (exclude those use	ed to treat rea	action)													
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER O7-AUG-2025  DATE OF THIS REPORT  25b. NAME AND ADDRESS WITHHELD.																		
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER O7-AUG-2025  DATE OF THIS REPORT  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER O7-AUG-2025  DATE OF THIS REPORT  25b. NAME AND ADDRESS WITHHELD.																		
UNKNOWN  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER O7-AUG-2025  24d. REPORT SOURCE STUDY LITERATURE PROFESSIONAL OTHER: Spontaneous  DATE OF THIS REPORT  25b. NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.		Y. (e.g. diagnostics, alle		nth of period,														
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA   24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  24d. REPORT SOURCE STUDY LITERATURE OTHER: Spontaneous  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.			Type of History / Notes		Description													
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA   24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  DATE OF THIS REPORT  25a. REPORT TYPE  26. REMARKS  26. REMARKS  26. REMARKS  27. ALGO ROSE  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA   24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  24d. REPORT SOURCE STUDY LITERATURE OTHER: Spontaneous  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA   24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  24d. REPORT SOURCE STUDY LITERATURE OTHER: Spontaneous  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA   24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  DATE OF THIS REPORT  25a. REPORT TYPE  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	04- NAME AND ADDRESS	AANII IFA OTI IDEE	IV. MANUF	ACTUR			101	1										
Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA  24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  DATE OF THIS REPORT  25a. REPORT TYPE  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	Pfizer S.A.				26. REN	ARKS												
24b. MFR CONTROL NO. PV202500072400  24c. DATE RECEIVED BY MANUFACTURER 07-AUG-2025  DATE OF THIS REPORT  25a. REPORT TYPE  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	Avenida Escazú, Torre Lexus, piso 7. Escazú																	
PV202500072400  AME AND ADDRESS WITHHELD.  AME AND ADDRESS WITHHELD.  AME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.  AME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.	Gair Jose, Goota No.																	
PV202500072400  AME AND ADDRESS WITHHELD.  AME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.		24b. MFR CONTF	ROL NO.		25b. NA	ME AND ADDR	RESS C	F REF	PORTER	R								
246. REPORT SOURCE STUDY OT-AUG-2025  DATE OF THIS REPORT  DATE OF THIS REPORT  DATE OF THIS REPORT  25a. REPORT TYPE  24d. REPORT SOURCE STUDY LITERATURE OTHER: Spontaneous  NAME AND ADDRESS WITHHELD.																		
07-AUG-2025  DATE OF THIS REPORT  25a. REPORT TYPE  25a. REPORT TYPE  25a. REPORT TYPE	24c. DATE RECEIVED BY MANUFACTURER	MANIJEACTIDED			NAME	NAME AND ADDRESS WITHHELD.												
DATE OF THIS REPORT 25a. REPORT TYPE		Z ALIO COOF			NAME AND ADDRESS WITHHELD.													
		25a. REPORT TY	PE															

### **ADDITIONAL INFORMATION**

#### 7+13. DESCRIBE REACTION(S) continued

or other non HCP and a Nurse from product quality group, Program ID: 164974.

A 14-year-old male patient received somatropin (GENOTROPIN PEN), first regimen (Batch/Lot number: unknown) till 2025 at 1.4 mg (1.4 mg (prescribed 1.5 mg)), second regimen (Batch/Lot number: unknown) at 1 mg daily and third regimen (Batch/Lot number: unknown) at 2 mg daily, Device Lot Number: L207, Device Expiration Date: 31Oct2026. The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: PRODUCT PRESCRIBING ERROR (non-serious), INCORRECT DOSE ADMINISTERED BY DEVICE (non-serious) all with onset 2025 and all described as "previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available"; DEVICE INFORMATION OUTPUT ISSUE (non-serious) with onset 2025, described as "the dosage wasn't showing properly/device was not displaying the dosage"; PRODUCT STORAGE ERROR (non-serious), described as "submerged the device in a container with ice and water, left it in the water, and it stopped displaying". The action taken for somatropin was unknown.

Additional Information: Caregiver stated: "I was calling because I needed an applicator. I didn't know if it was due to humidity or something else, but I couldn't see the dosage". When asked about the dosage used, she explained: "The doctor had changed it. I was going to pick it up again. She had increased the dose to 2 mg; previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available. Now, I wasn't sure if the humidity from refrigeration was affecting it, but the dosage wasn't showing properly. At that moment, she wasn't administering it because she was planning to restart. She had been giving it based on what she believed was correct, turning the applicator as the nurse had previously instructed. But since around Holy Week, the dosage hadn't been visible. As the treatment was nearing its end, she decided to wait and see if the doctor would prescribe it again. After their appointment last week, when the doctor did prescribe it again, she decided to call to see if the device could be replaced. She also mentioned that if there was a pharmacy where she could buy it, she would do so without any problem". On 18Jun2025, the reporter stated that their answer was related to the sample being available, just do not know what they would use to administer the medication. Upon a follow-up received on 19Jun2025, patient's mother reported via email: "My answer is related to the sample being available, I just don't know what I would use to administer the medication". Then, regarding about missed doses: "Of course not, I was setting the doses based on the number of turns, but now the dose has been increased and I don't know how many turns that would be. In any case, I'll wait to see if the humidity settles". As of 26Jun2025, nurse indicated that the patient's mother submerged the device in a container with ice and water, left it in the water, and it stopped displaying. Upon a follow-up received on 26Jun2025, the patient's caregiver stated that the day before, a nurse had visited to check the ampoule applicator. The nurse informed her that she would report the issue so the device could be replaced. However, no one had contacted her since, and she was unsure how to administer the medication to the child, as the device was not displaying the dosage. Additionally, the caregiver mentioned that she used to inject 1.5 mg to the patient, and the treatment was intended to last for two months

Causality for "the dosage wasn't showing properly/device was not displaying the dosage", "previously it was 1.5 mg, but we were administering 1.4 mg because 1.5 wasn't available" and "submerged the device in a container with ice and water, left it in the water, and it stopped displaying" was determined associated to device constituent of somatropin (malfunction).

Follow-up (18Jun2025 and 19Jun2025): This is a spontaneous follow-up report received from a Consumer or other non HCP from product quality group. Updated information included: Product information (lot# and expiration date), event information (event Intentionally missed dose recoded to Drug dose omission by device, event Incorrect dose administered by device deleted), Clinical course details added.

Follow-up (19Jun2025): This is a spontaneous follow-up report received from product quality group. Updated information: event removed ("At that moment, she wasn't administering it because she was planning to restart"), product details and clinical course.

Follow-up (26Jun2025): This is a spontaneous follow-up report received from reporter(s) Consumer. Updated information: Dosage regimen, new event (submerged the device in a container with ice and water, left it in the water, and it stopped displaying) and clinical course

Follow-up (26Jun2025): This is a spontaneous follow-up report received from a Consumer.

Updated information: New event added (Incorrect dose administered by device), product details (dosage regimen) and clinical course. Follow-up (07Aug2025): Follow-up attempts are completed. Batch/lot number is not provided, and it cannot be obtained.

#### 14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) Genotropin Pen (SOMATROPIN) Solution	1 mg, daily; Unknown	Unknown	Unknown;
for injection; Regimen #2			Unknown

# **ADDITIONAL INFORMATION**

## 14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) Genotropin Pen (SOMATROPIN) Solution for injection; Regimen #3	2 mg, daily; Unknown	Unknown	Unknown; Unknown
#2 ) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection {Lot # L207}; Regimen #1	; Unknown	Unknown	Unknown; Unknown